TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9278200

Group type: EXPERIMENTAL
Intervention: Aspirin 750 mg, three times a day for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7865647

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Omeprazole 20 mg weekend
Number of subjects: 81
Study: 2577500

Group type: EXPERIMENTAL
Intervention: SK&F 94482 (BMY-25368) 400 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 778649

Group type: EXPERIMENTAL
Intervention: Furosemide (1.5 to 6.0 mg/kg every 4 h)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no furosemide)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 66
Study: 31535302

Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG, n=87)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional follow-up schedule group (CSG, n=93)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG)
Number of subjects: 180
Study: 31375523

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laparoscopic greater curvature plication
Number of subjects: 45

Group type: COMPARATOR
Intervention: RYGB or SG (in validation cohort)
Number of subjects: 45

Group type: COMPARATOR
Intervention: RYGB or SG (in derivation cohort)
Number of subjects: 45
Study: 28585840

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 44
Study: 24859784

Group type: EXPERIMENTAL
Intervention: 1970s baseline measurements
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: 2000s follow-up measurements
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Shared genetic contribution
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Shared environmental contributions
Number of subjects: 1454
Study: 22554102

Group type: EXPERIMENTAL
Intervention: 0.13% hyaluronic acid (HA) solution
Number of subjects: 196

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 196
Study: 20981007

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: ADRB2 promoter polymorphisms
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: ADRB2 promoter haplotype
Number of subjects: 369
Study: 18580199

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted colectomy (LAC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 219
Study: 15743923

Group type: EXPERIMENTAL
Intervention: Low-dose cocaine (75 mg/70 kg) and codeine (60 mg/70 kg) administered subcutaneously and orally on alternating days for a total of three doses each during week 4.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose cocaine (150 mg/70 kg) and codeine (120 mg/70 kg) administered during week 7.
Number of subjects: 10
Study: 12218280

Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with toothpaste containing 1,000 ppm fluoride and 0.13% calcium glycerophosphate on school-days, combined with recommended daily home use.
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group with no intervention other than 6-monthly clinical examinations.
Number of subjects: 534
Study: 10341404

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 115

Group type: COMPARATOR
Intervention: Non-pregnant women (control)
Number of subjects: 115
Study: 8563385

Group type: EXPERIMENTAL
Intervention: Computerized preadmission screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection, intervention, and compliance factors
Number of subjects: 0
Study: 2672807

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg three times daily (n = 113)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (n = 109)
Number of subjects: 222
Study: 362875

Group type: EXPERIMENTAL
Intervention: Migen vaccine (6-injection course)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Migen vaccine (6-injection course + 6 maintenance injections)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (12 injections)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Migen vaccine (standard course of 6 injections)
Number of subjects: 28
Study: 31871223

Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Number of subjects: 19981

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 19981
Study: 30755410

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine replacement therapies (patches and gum)
Number of subjects: 0
Study: 28646590

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg) plus conventional therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo plus conventional therapy
Number of subjects: 33
Study: 26113676

Group type: EXPERIMENTAL
Intervention: Everolimus (2.5 mg·day(-1) escalated to 10 mg·day(-1))
Number of subjects: 24
Study: 24132082

Group type: EXPERIMENTAL
Intervention: Soft tissue impacted third molar
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Erupted third molar
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Bony impacted third molar
Number of subjects: 416

Group type: COMPARATOR
Intervention: Absent third molar
Number of subjects: 416
Study: 21597124

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT); 2, 2-hour group sessions.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Education; 2, 2-hour group sessions.
Number of subjects: 54
Study: 19954709

Group type: EXPERIMENTAL
Intervention: TJ‐48 (7.5 g per day from 21 days before surgery to the day before surgery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no TJ‐48)
Number of subjects: 18
Study: 16912578

Group type: EXPERIMENTAL
Intervention: Weekly idursulfase (0.5 mg/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Every-other-week idursulfase (0.5 mg/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 15549370

Group type: EXPERIMENTAL
Intervention: Lumbar extensor fatigue (fatigued to 60% of unfatigued maximum voluntary exertion force)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fatigue rate (fatigued over either 10 min or 90 min)
Number of subjects: 13
Study: 11384805

Group type: EXPERIMENTAL
Intervention: 20% human albumin 50 ml (n: 82)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) 500 ml (n: 85)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (500 ml 0.9% NaCl solution) (n: 83)
Number of subjects: 250
Study: 9436574

Group type: EXPERIMENTAL
Intervention: Heparin-bonded oxygenator (group H, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonbonded oxygenator (group C, n = 10)
Number of subjects: 21
Study: 8299434

Group type: EXPERIMENTAL
Intervention: Adherence to prescribed meal plan
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Adjusting food and/or insulin in response to hyperglycemia
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Over-treating hypoglycemia
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Consuming extra snacks beyond the meal plan
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Adjusting insulin dose for meal size and content
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Consistent consumption of an evening snack
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Specific diet-related behaviors
Number of subjects: 623
Study: 3566457

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unilateral ECT
Number of subjects: 52
Study: 30157683

Group type: EXPERIMENTAL
Intervention: ERC1671 plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 0
Study: 25875425

Group type: EXPERIMENTAL
Intervention: FMUD + PVPI (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: FMUD + SS (n=14)
Number of subjects: 28
Study: 24118850

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with leuprorelin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Zometa
Number of subjects: 39
Study: 22457045

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PRPplus
Number of subjects: 20
Study: 20163323

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study: 18458958

Group type: EXPERIMENTAL
Intervention: Amitriptyline (short-term use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (short-term use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (short-term use)
Number of subjects: 0
Study: 16385649

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (200 mg daily for 2 weeks every 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alendronate (5 mg daily)
Number of subjects: 50
Study: 14674833

Group type: EXPERIMENTAL
Intervention: 4.16-androstadien-3-one (AND)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: l,3,5(10),16-estratetraen-3-ol (EST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 10620210

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) alone, N = 11
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Daily oral calcitriol, N = 20
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous calcitriol, N = 21
Number of subjects: 52
Study: 8871414

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Automatic Thoughts (AT) treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 150
Study: 1514533

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation (magnesium sulphate, 3 g before each CDDP administration)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (magnesium pidolate, 2 g orally every 8 hours on days 2 to 21 of each CDDP course)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No magnesium supplementation (control group)
Number of subjects: 41
Study: 6392354

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Codeine 90 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 31542755

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study: 29653328

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) therapy
Number of subjects: 74
Study: 27717298

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study: 25274719

Group type: EXPERIMENTAL
Intervention: 12-month SDT-based lifestyle intervention
Number of subjects: 221
Study: 22905160

Group type: EXPERIMENTAL
Intervention: Bamboo skirt intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dhoincha skirt intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Jute stick skirt intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Polythene covering intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 21057561

Group type: COMPARATOR
Intervention: IL‐10‐1082 A/A homozygous genotype in benign brain tumors
Number of subjects: 45

Group type: COMPARATOR
Intervention: IL‐6‐174 C/C homozygous genotype in benign brain tumors
Number of subjects: 45

Group type: COMPARATOR
Intervention: IL‐6‐174 C/C homozygous genotype in malignant brain tumors
Number of subjects: 45

Group type: COMPARATOR
Intervention: TNF‐a‐308 A/A homozygous genotype in malignant brain tumors
Number of subjects: 45

Group type: COMPARATOR
Intervention: IL‐1Ra VNTR genotype polymorphism
Number of subjects: 45
Study: 17689147

Group type: EXPERIMENTAL
Intervention: Miglustat 200 mg three times a day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 29
Study: 15451149

Group type: EXPERIMENTAL
Intervention: Age (independent predictor of short-term mortality)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Age (independent predictor of long-term mortality)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Age and LV systolic dysfunction interaction
Number of subjects: 34
Study: 11271867

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 129
Study: 10021953

Group type: EXPERIMENTAL
Intervention: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during thoracic epidural anaesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol administration (2 mg.kg‐1 at a rate of 200 mg.min‐1, followed by continuous infusion of 4 mg.kg‐1.hr‐1) during lumbar epidural anaesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group receiving general anaesthesia alone
Number of subjects: 45
Study: 7920873

Group type: EXPERIMENTAL
Intervention: Exercise and diet modification training program (1 session per week for 8 weeks, including 20 min of walking)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exercise and diet modification training program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 3171374

Group type: EXPERIMENTAL
Intervention: Benzocaine lozenges (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29543567

Group type: EXPERIMENTAL
Intervention: Edinburgh Pain Assessment and Management Tool (EPAT)
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: EPAT (after excluding two centers that failed to implement)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: EPAT
Number of subjects: 1921

Group type: COMPARATOR
Intervention: EPAT and UC
Number of subjects: 1921
Study: 27049915

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Active DBS
Number of subjects: 25
Study: 25432788

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg starting dose, oral once-daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24645611

Group type: EXPERIMENTAL
Intervention: Polylactic acid gel (PLA-G) used under the surface of the auxiliary operative wound in the treatment group.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with no intervention (nothing used).
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control).
Number of subjects: 68
Study: 20064022

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment applied 3 times a day for 16 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo ointment applied 3 times a day for 16 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 144
Study: 18562776

Group type: EXPERIMENTAL
Intervention: Artichoke-leaf extract, 400 mg, 3 times a day for 5 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Artichoke-leaf extract
Number of subjects: 22
Study: 16999007

Group type: EXPERIMENTAL
Intervention: Stannous fluoride/sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Triclosan/copolymer control dentifrice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 80
Study: 12015788

Group type: EXPERIMENTAL
Intervention: 10 mg ER-lovastatin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg ER-lovastatin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg ER-lovastatin
Number of subjects: 9
Study: 10495050

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus (stimulation 'on')
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the VIM nucleus of the thalamus (stimulation 'off')
Number of subjects: 38
Study: 8610317

Group type: EXPERIMENTAL
Intervention: Serial B‐mode measurements of carotid IMT
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: ACAPS measurement protocol
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Follow-up times of 2 years or more
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Follow-up times of 6 years or more
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Sample sizes as low as 237
Number of subjects: 237
Study: 1792411

Group type: EXPERIMENTAL
Intervention: Bamiphylline (1.2 g daily for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7303692

Group type: EXPERIMENTAL
Intervention: Clopenthixol (Sordinol, Ciatyl) in small dosage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not treated with clopenthixol)
Number of subjects: 58
Study: 30865916

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 1

Group type: COMPARATOR
Intervention: Unselected group of patients with UC (N=17)
Number of subjects: 1
Study: 28376818

Group type: EXPERIMENTAL
Intervention: E-cigarettes (nicotine-free and nicotine-inclusive) with behavioral support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) with behavioral support
Number of subjects: 0
Study: 26355674

Group type: EXPERIMENTAL
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 833

Group type: COMPARATOR
Intervention: dolutegravir (DTG) + abacavir/lamivudine (ABC/3TC)
Number of subjects: 833
Study: 22943633

Group type: EXPERIMENTAL
Intervention: Blueberry juice (BBJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen with BBJ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole (positive control)
Number of subjects: 0
Study: 21272897

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (3 10-minute cycles of lower limb ischemia and reperfusion)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 19531462

Group type: EXPERIMENTAL
Intervention: Health development program package (3-month duration)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 125
Study: 15888512

Group type: EXPERIMENTAL
Intervention: High-dose acute tryptophan depletion (ATD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose acute tryptophan depletion (ATD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study: 12563237

Group type: EXPERIMENTAL
Intervention: Aggressive fluid management (16 to 18 mL x kg(‐1) x h(‐1))
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conservative fluid management (8 mL x kg(‐1) x h(‐1))
Number of subjects: 56
Study: 10383528

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 16
Study: 8767949

Group type: EXPERIMENTAL
Intervention: Short incision (2.5 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long incision (4.5 cm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic release
Number of subjects: 0
Study: 1916034

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 08.00 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 22.00 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6226480

Group type: EXPERIMENTAL
Intervention: Oral challenge with a mixture of 2.5 mg nickel, 2.5 mg chromium, and 1 mg cobalt salts
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diet planned to reduce daily intake of respective metals
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diet adherence
Number of subjects: 202
Study: 30747604

Group type: EXPERIMENTAL
Intervention: D-allulose (D-psicose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-tagatose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-sorbose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-allose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural sweeteners (stevia, monk fruit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial sweeteners
Number of subjects: 0
Study: 28732525

Group type: EXPERIMENTAL
Intervention: 40 hours of simulated placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 hours of traditional placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional placement
Number of subjects: 0
Study: 26372082

Group type: EXPERIMENTAL
Intervention: Half-sized food portions with modest nonfood incentives (e.g., inexpensive headphones for children, gift cards or frequent flyer miles for adults, small amounts of money for restaurant customers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-sized food portions without nonfood incentives
Number of subjects: 0
Study: 22954666

Group type: EXPERIMENTAL
Intervention: Exemestane (25mg daily) alone
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Tamoxifen (20mg daily) followed by exemestane
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Exemestane (25mg daily)
Number of subjects: 2603
Study: 21082252

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention for 7 months
Number of subjects: 198
Study: 19846851

Group type: EXPERIMENTAL
Intervention: Cisplatin alone (80 mg/m² every 14 days)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin (administered in three preoperative cycles and two postoperative cycles)
Number of subjects: 255